ES2764480T8 - Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato - Google Patents

Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato

Info

Publication number
ES2764480T8
ES2764480T8 ES09738172T ES09738172T ES2764480T8 ES 2764480 T8 ES2764480 T8 ES 2764480T8 ES 09738172 T ES09738172 T ES 09738172T ES 09738172 T ES09738172 T ES 09738172T ES 2764480 T8 ES2764480 T8 ES 2764480T8
Authority
ES
Spain
Prior art keywords
acamprosate
zonisamide
disease
related disorders
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09738172T
Other languages
English (en)
Other versions
ES2764480T3 (es
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Oxana Guerassimenko
Nathalie Cholet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext SA filed Critical Pharnext SA
Application granted granted Critical
Publication of ES2764480T3 publication Critical patent/ES2764480T3/es
Publication of ES2764480T8 publication Critical patent/ES2764480T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09738172T 2008-04-29 2009-04-29 Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato Active ES2764480T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4858208P 2008-04-29 2008-04-29
PCT/EP2009/055176 WO2009133128A1 (en) 2008-04-29 2009-04-29 Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Publications (2)

Publication Number Publication Date
ES2764480T3 ES2764480T3 (es) 2020-06-03
ES2764480T8 true ES2764480T8 (es) 2020-07-24

Family

ID=40848096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09738172T Active ES2764480T3 (es) 2008-04-29 2009-04-29 Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato

Country Status (15)

Country Link
US (3) US20110269764A1 (es)
EP (2) EP3560496A1 (es)
JP (2) JP5933258B2 (es)
KR (1) KR20110071050A (es)
CN (2) CN104127434B (es)
AU (1) AU2009242113B2 (es)
BR (1) BRPI0911874A2 (es)
CA (1) CA2722295C (es)
EA (1) EA024147B1 (es)
ES (1) ES2764480T3 (es)
IL (2) IL208981B (es)
MX (1) MX2010011878A (es)
NZ (1) NZ589304A (es)
WO (1) WO2009133128A1 (es)
ZA (1) ZA201008038B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
EP3560496A1 (en) * 2008-04-29 2019-10-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
TR201809351T4 (tr) 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
CN104487064B (zh) * 2012-03-01 2018-01-26 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
JP6430445B2 (ja) * 2011-03-01 2018-11-28 ファーネクストＰｈａｒｎｅｘｔ バクロフェンおよびアカンプロセートに基づく神経疾患の治療
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
RS56175B1 (sr) * 2012-03-01 2017-11-30 Pharnext Nove kompozicije za lečenje amiotrofične lateralne skleroze
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10626163B2 (en) 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
CN103040800A (zh) * 2013-01-28 2013-04-17 杭州雷索药业有限公司 吉非罗齐在制备抗血管生成类药物中的应用
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
WO2016157175A1 (en) * 2015-03-27 2016-10-06 Yeda Research And Development Co. Ltd. Methods of treating motor neuron diseases
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
EP3506927A4 (en) 2016-08-03 2020-05-06 University of South Florida REELIN COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN111050761A (zh) 2017-04-24 2020-04-21 法奈克斯公司 阿尔茨海默病的基于idalopirdine的组合治疗
JP7321097B2 (ja) * 2017-04-26 2023-08-04 カビオン・インコーポレイテッド 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法
AU2018271895A1 (en) * 2017-05-26 2020-01-16 Chase Therapeutics Corporation Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
US10393760B2 (en) 2017-07-05 2019-08-27 Edward J. Goetzl Specialized excitatory synaptic protein biomarkers of plasma neuronal exosomes for prediction and staging of Alzheimer's disease
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
IL300798B2 (en) 2018-10-03 2025-09-01 Cavion Inc Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
WO2020123449A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
CN109402124A (zh) * 2018-12-11 2019-03-01 宁夏医科大学总医院 一种环状RNA hsa-circ-0006969及其特异性扩增引物和应用
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
EP4151213A4 (en) * 2020-05-11 2024-05-29 Shimadzu Corporation THERAPEUTIC FOR MILD COGNITIVE IMPAIRMENT
JP2024534268A (ja) 2021-08-31 2024-09-18 セレスピア インコーポレイテッド 共結晶

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727278B1 (en) * 1986-08-27 2004-04-27 Dms Pharmaceutical Inc. Pharmaceutically active agents that impede amyloid formation in vivo
JP2654688B2 (ja) * 1989-05-17 1997-09-17 東燃株式会社 オレフィン重合用触媒成分
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
ES2244103T3 (es) * 1997-12-26 2005-12-01 Dainippon Pharmaceutical Co., Ltd. Remedio para enfermedades neurodegenerativas.
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
HUP0104993A3 (en) * 1998-11-02 2003-02-28 Alza Corp Mountain View Method and device for controlled delivery of active agents
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
KR20070104953A (ko) * 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
JP2003113120A (ja) * 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
EP1474158B1 (en) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1523310A2 (en) * 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
WO2005090994A2 (en) * 2004-03-24 2005-09-29 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
CN101166516A (zh) * 2005-01-21 2008-04-23 特瓦制药工业有限公司 稳定的唑尼沙胺药物制剂及其制备方法
WO2006110588A2 (en) * 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1928445A1 (en) * 2005-09-16 2008-06-11 Cereuscience AB Method and means of preventing and treating sleep disordered breathing
DK1954241T3 (da) * 2005-11-28 2012-06-18 Orexigen Therapeutics Inc Zonisamid-formulering med vedvarende frigivelse
WO2008010768A1 (en) * 2006-07-17 2008-01-24 Cereuscience Ab Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
WO2008141074A1 (en) * 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
EP3560496A1 (en) * 2008-04-29 2019-10-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EA019571B1 (ru) * 2008-04-29 2014-04-30 Фарнекст Применение сульфизоксазола для лечения болезни альцгеймера
AU2009242126B2 (en) * 2008-04-29 2014-03-27 Pharnext New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis
US9387206B2 (en) * 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease

Also Published As

Publication number Publication date
US20190298698A1 (en) 2019-10-03
CN104127434B (zh) 2017-10-13
WO2009133128A1 (en) 2009-11-05
US20110269764A1 (en) 2011-11-03
ES2764480T3 (es) 2020-06-03
EP2285374A1 (en) 2011-02-23
CA2722295A1 (en) 2009-11-05
CN102065858A (zh) 2011-05-18
AU2009242113A1 (en) 2009-11-05
ZA201008038B (en) 2011-08-31
US20160136136A1 (en) 2016-05-19
AU2009242113B2 (en) 2014-09-11
JP2014205697A (ja) 2014-10-30
EA201071243A1 (ru) 2011-06-30
EA024147B1 (ru) 2016-08-31
CA2722295C (en) 2019-01-15
BRPI0911874A2 (pt) 2018-05-22
CN104127434A (zh) 2014-11-05
JP5933258B2 (ja) 2016-06-08
CN102065858B (zh) 2014-07-02
JP2011518860A (ja) 2011-06-30
IL208981A0 (en) 2011-01-31
EP2285374B1 (en) 2019-09-18
IL208981B (en) 2019-02-28
MX2010011878A (es) 2011-04-11
US10874644B2 (en) 2020-12-29
IL264736B (en) 2020-05-31
KR20110071050A (ko) 2011-06-28
US10350195B2 (en) 2019-07-16
NZ589304A (en) 2012-03-30
EP3560496A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
ES2764480T8 (es) Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
IL213259A0 (en) Composition for the use to treat alzheimer's disease
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0914385A2 (pt) "composição antiperspirante ou desodorante e processo para a fabricação de uma composição antiperspirante ou desodorante"
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
IL219412A (en) Preparations containing Busimanden for use in the treatment of Alzheimer's or Alzheimer's disease
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0808950B8 (pt) "composições de cuidados pessoais"
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
BRPI0813553A2 (pt) composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI1007603A2 (pt) "composição de tratamento do cabelo"
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
BRPI0810947A2 (pt) "composição de condicionamento de cabelos"
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho